Latest news
Artiva Therapeutics: Buy Rating Reiterated on Strong AlloNK RA Profile and Upcoming Phase III, Price Target Maintained at $41 - TipRanksTipRanks · Fri, 07 Aug 2026 10:59:49 GMTArtiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Yahoo! Finance CanadaYahoo! Finance Canada · Thu, 06 Aug 2026 20:05:00 GMT